GlassScriptPhysician profile
Roy W Gernhardt
NPI 1215071972
$2,897.40
in general payments reported to CMS, 2019-2025
35 companies · $425 in 2025
The $425 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $528 · 2020: $435 · 2021: $524 · 2022: $424 · 2023: $375 · 2024: $187 · 2025: $425.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $987.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $986.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $403.78 | 2019-2025 | Rybelsus, Ozempic |
| Abbvie INC. | $334.80 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $318.15 | 2019-2024 | Airsupra, Farxiga |
| Takeda Pharmaceuticals U.S.A., INC. | $222.74 | 2019-2022 | |
| Lilly USA, LLC | $177.71 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $162.30 | 2019-2025 | Xifaxan |
| E.R. Squibb & Sons, L.L.C. | $136.10 | 2019-2025 | Eliquis, Camzyos |
| Abbott Laboratories | $128.55 | 2021-2024 | Freestyle Libre 3, Freestyle Libre 2 |
| Pfizer INC. | $114.77 | 2019-2025 | |
| Glaxosmithkline, LLC. | $108.35 | 2019-2025 | Arexvy |
| Indivior INC. | $104.43 | 2019-2025 | Sublocade |
| Collegium Pharmaceutical, INC. | $84.66 | 2020-2025 | Xtampza |
| Bayer Healthcare Pharmaceuticals INC. | $66.08 | 2025 | |
| Orexo US, INC. | $58.54 | 2019-2020 | |
| Exact Sciences Corporation | $46.76 | 2024-2025 | Cologuard Collection Kit |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biodelivery Sciences International, INC. | $40.55 | 2020-2021 | |
| Sanofi-Aventis U.S. LLC | $34.02 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $28.03 | 2020-2025 | Jardiance |
| Biofire Diagnostics, LLC | $27.87 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $27.74 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $26.67 | 2023 | Spravato |
| Avanir Pharmaceuticals, INC. | $26.26 | 2019 | |
| Phathom Pharmaceuticals, INC. | $26.09 | 2024-2025 | Voquezna |
| Shire North American Group INC | $24.93 | 2019 | |
| Allergan, INC. | $23.85 | 2019 | |
| Merck Sharp & Dohme LLC | $22.82 | 2019 | |
| Braeburn INC. | $22.18 | 2025 | Brixadi |
| Biogen, INC. | $13.71 | 2022 | |
| Alkermes, INC. | $13.04 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $12.42 | 2022 | |
| Daiichi Sankyo INC. | $12.19 | 2019 | |
| Grt US Holding, INC. | $11.98 | 2022 | |
| Lundbeck LLC | $11.94 | 2022 | |
| Kaleo, INC. | $11.88 | 2021 | |
| Qol Medical, LLC | $11.51 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roy Gernhardt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.